conducting a dose-response. This is reinforced by the report by Schrage et al., 6 who required a concentration range of 1-5 mg/mL IVIg to demonstrate the inhibition of 12 different superantigens. Moreover, these authors found that most commercial IVIg preparations had even better neutralizing activity than the preparation used in our study, reaffirming the point regarding the source of IVIg.
The main purpose of our study was to evaluate IVIg action on inflammation and outcome in S. pyogenes infection, rather than to re-evaluate the in vitro activity of IVIg against purified superantigens. For this reason, the superantigen-inhibiting properties of IVIg were assessed as a preliminary step only. Culture supernatants were used rather than purified superantigens, as these are representative of both the mixture of superantigens and concentrations that prevail in patients. 8 Streptococcal mitogenic exotoxin Z ('SMEZ') is active at 10 fg/mL and is normally found in nature at levels of less than 10 pg/mL, 8, 9 whereas Rajagopalan et al. used a superantigen concentration several logs in excess of this. Although not the major focus, our data showed unequivocally that IVIg could quantitatively inhibit the mitogenic actions of the superantigens produced by S. pyogenes both in vitro and, from the infection studies, in vivo as well. Nonetheless, IVIg 1 mg/kg was insufficient to completely neutralize superantigen mitogenicity during S. pyogenes infection. 7 It is therefore perhaps unsurprising that Rajagopalan et al. found that proportionate expansion of T-cell subsets expressing relevant TCR Vb families was unaltered in mice treated with 1 mg/kg IVIg as this may simply be a consequence of residual Vb-specific effects, notwithstanding quantitative effects of IVIg on mitogenicity and blast formation.
The key questions arising from our study include, first, whether the modulation of inflammation and bacterial clearance provided by IVIg in S. pyogenes-infected HLA-DQ8 mice has anything to do with the ability of IVIg to inhibit superantigeninduced mitogenesis? IVIg has several additional potentially protective actions, and studies are on-going to evaluate these. Secondly, it remains unclear if IVIg can confer additional benefit to 'gold standard' therapy in human streptococcal toxic shock, as, in HLA-DQ8 mice, this was not evident. 1 Furthermore, the eradication rate of H. pylori infection is low, mainly due to a considerable number (37%) of metronidazole-resistant strains.
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2 Accordingly, investigators have been trying to substitute this antibiotic. Since fatty acids, namely cholesteryl glucosides, have been found in the cell membrane of Helicobacter species, investigators have speculated that imidazole antimycotics such as ketoconazole might interfere with the biosynthesis of these fatty acids from cholesterol. 3 The dual activity of ketoconazole against both H. pylori and fungi might be valuable because oral yeasts have been proposed as potent reservoirs as well as protective vehicles for transmission of H. pylori to the human gastrointestinal tract. 4 Thus design of chemotherapeutic regimens containing ketoconazole will benefit patients by eradicating H. pylori as well as reducing the number of yeast microflora harbouring H. pylori.
In this study the antibacterial activity of ketoconazole against metronidazole-resistant and -susceptible strains of H. pylori was assessed by agar dilution method (ADM) and disc diffusion method (DDM and 2 mg/L. Among fifteen isolates, five were resistant to metronidazole. Aliquots (5 mL) of bacterial suspensions with turbidities equivalent to that of a no. 2 McFarland standard were spot-inoculated on the surface of agar plates. Plates were examined after 3 days of microaerobic incubation and MICs were determined. Similar bacterial suspensions of Escherichia coli were spot-inoculated on Mueller-Hinton agar plates with serial dilutions of ketoconazole (128-4 mg/L). In DDM, serial dilutions of ketoconazole (32, 16, 8, 4 and 2 mg/L) were prepared in DMSO. Among 35 recruited isolates, eleven were metronidazole-resistant. Aliquots (100 mL) of bacterial suspensions were surface-inoculated on Mueller-Hinton blood agar. Each ketoconazole dilution (10 mL) was introduced into paper discs on the surface of the agar. After microaerobic incubation, growth inhibition zones were measured. Strains with inhibition zone diameters (IZDs) of 17-21 and >21 mm were considered as susceptible and highly susceptible, respectively.
Out of 50 isolates, 16 (32%) were resistant to metronidazole. Susceptibility to ketoconazole for 14/15 (93.3%) isolates recruited in ADM was determined at MIC 8 mg/L, although 8/15 (53.3%) were also inhibited at MIC 4 mg/L and one (6.6%) was inhibited at an MIC of 16 mg/L. Five out of 15 isolates that were resistant to metronidazole showed high susceptibility to ketoconazole. Control E. coli exhibited growth on plates containing 128 mg/L ketoconazole. In DDM, the means of IZDs for 35 H. pylori isolates at different dilutions of ketoconazole were determined ( Table 1) . Susceptibility of bacterial isolates was determined according to IZDs at 8 mg/L. Nineteen isolates (54.1%) were susceptible and 16 isolates (45.9%) were highly susceptible to ketoconazole. Among 11 metronidazole-resistant strains, 7 (63.6%) were susceptible and 4 (36.4%) were highly susceptible to ketoconazole. H. pylori isolates from patients with gastritis, gastric ulcer or cancer were similarly susceptible to ketoconazole.
All the 50 isolates were inhibited by ketoconazole, although E. coli was highly resistant. The MIC of ketoconazole was determined as 8 mg/L in both ADM and DDM. Similarly, inhibitory concentrations of the antimycotic miconazole (MIC 2-32 mg/L) against H. pylori have been reported. 5 Ketoconazole can be considered as a substitute for metronidazole. Regarding the safety of ketoconazole, it is proposed that the dose required to inhibit mammalian cells is much higher than that required for fungi 6 or bacteria. 5 Since the intracellular existence of H. pylori in yeast plays an important role in the persistence of H. pylori in the human oral cavity, 4 administration of ketoconazole not only leads to eradication of H. pylori, but might also reduce the chance of recurrence of bacterial infection by affecting colonization of yeasts in the gastrointestinal tract. Correspondence
